CN101336910A - Chlorhexidine composition with colouring function - Google Patents
Chlorhexidine composition with colouring function Download PDFInfo
- Publication number
- CN101336910A CN101336910A CNA2008101475214A CN200810147521A CN101336910A CN 101336910 A CN101336910 A CN 101336910A CN A2008101475214 A CNA2008101475214 A CN A2008101475214A CN 200810147521 A CN200810147521 A CN 200810147521A CN 101336910 A CN101336910 A CN 101336910A
- Authority
- CN
- China
- Prior art keywords
- compositions
- ethanol
- hibitane
- salt
- coloring agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a hibitane composition with coloring function, which comprises hibitane or a pharmaceutically-acceptable salt thereof and at least one coloring agent. The inventive composition also comprises a pharmaceutically-acceptable carrier.
Description
Technical field:
The present invention relates to a kind of is the compositions of active constituents of medicine with the hibitane, particularly a kind of chlorhexidine composition that adds coloring agent.
Background technology:
Hibitane is synthetic first in the laboratory of Britain one family research antimalaric in nineteen fifty.Discover that hibitane has high antibiotic, to the mammal low toxicity and depend on the strong performance of skin ability.More than these performances impel people to research and develop the natural anti-corrosion additive of chlorhexidine gluconate (CHG).
Chlorhexidine gluconate has been used for surplus the skin degerming 30 year in Europe, Asia and Canada, chlorhexidine gluconates in 1977 are also crossed the examination of Food and Drug Administration at Americanologist, use as the surgical operation handwashing liquid, in July, 2000, Food and Drug Administration ratified 2% chlorhexidine gluconate and 70% ethanol again as disinfectant preparation before patient's art.
Ethanol is as the solvent of CHG, and itself also has very strong sterilizing ability, and it can produce the antibiosis effect by character and the decomposition cytolipin that changes cell protein.Its sphere of action extensively all has the good sterilization effect to most of Gram-positive microorganism and Gram-negative microorganism, and the energy useful effect comprises respiratory syncytial virus, hepatitis B and HIV (human immunodeficiency virus) (HIV) in a lot of funguses and virus.
Existing hibitane preparation mostly is colourless.The particularly very fast in use volatilization of varnish of liquid preparation leaves no trace, and some patients also thinks not used after using, and reuses, and causes repeatedly using and damages skin.
The present invention adds medical pigment in the compositions of hibitane through research, adds in compositions simultaneously that ethanol preparation goes out to take effect rapidly, lasting medicine, effect is superpower and have the skin degerming product of colouring function.
Summary of the invention:
The invention provides a kind of pharmaceutical composition that contains hibitane or its pharmaceutically acceptable salt and at least a coloring agent.
Compositions of the present invention also contains the medicine acceptable carrier.
Compositions of the present invention, the salt of described hibitane is hibitane and mineral acid or the formed salt of organic acid, is selected from hydrochlorate, hydrobromate, phosphate, sulfate, acetate, trifluoroacetate, citrate, maleate, oxalates, succinate, benzoate, tartrate, fumarate, mandelate, Ascorbate, malate, mesylate, tosilate, gluconate or acetate.Preferably gluconate and acetate.
Compositions of the present invention is to be fit to medicinal dosage form, is selected from an innings ointment, solution, suppository, lotion, cream, obedient agent, varnish, mixture.
Compositions of the present invention, wherein said coloring agent are that medical science and pharmacology go up acceptable any pigment.Be selected from sunset yellow, lemon yellow, Gentian Violet, red, the bright orchid of relation by marriage fat.
Compositions of the present invention comprises: the salt of hibitane, at least a coloring agent, ethanol or isopropyl alcohol, water preferred the composition.
Compositions of the present invention, it is composed as follows preferably to fill a prescription
The salt 0.5-5% of hibitane
Ethanol 50-90%
Coloring agent 0.5-1.5%
All the other are water.
Compositions of the present invention, particularly preferred prescription is composed as follows
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
Sunset yellow 0.8kg
Water surplus
Make 100L
Its preparation method is as follows:
Be the dissolving of 20% chlorhexidine gluconate with pure water with 10kg concentration earlier, mix and stirred 5 minutes;
Add 70L concentration again and be 99.9% ethanol, mix to stir and add the sunset yellow of 0.8kg and an amount of wetting agent after 5 minutes, stabilizing agent, and pure water evenly stirred 10 minutes;
Censorship, fill, encapsulation.
Below the representational drug products of the present invention is carried out effect experiment, with experimental data beneficial effect of the present invention is described.
Experiment one, antibiotic time and power evaluation test:
With the sample of the present invention that makes among the embodiment 1 disinfectant solution solvent as experiment usefulness.
Before experiment, be ready to the cultivation liquid of each experiment microorganism, and the bacterial number of the good every kind of microorganism of test.Detection, spread upon disinfectant solution solvent of the present invention in 14 kinds of modal microorganisms in 30 seconds in 15 seconds, the results are shown in Table 1.
Table 1. is smeared the slip of bacterial flora behind this disinfectant solution solvent
| Enterococcus faecalis | Enterococcus faecalis | Escherichia coli | The white Salmonella of Cray | Cray Bai Shi pulmonitis strain | The variation Bacillus proteus | Pseudomonas aeruginosa | |
| 15 seconds | ＞7.06 ＞99.9％ | ＞5.59 ＞99.9％ | ＞6.95 ＞99.9％ | ＞5.88 ＞99.9％ | ＞5.87 ＞99.9％ | ＞6.04 ＞99.9％ | ＞5.82 ＞99.9％ |
| 30 seconds | ＞7.06 ＞99.9％ | ＞5.59 ＞99.9％ | ＞6.95 ＞99.9％ | ＞5.88 ＞99.9％ | ＞5.87 ＞99.9％ | ＞6.04 ＞99.9％ | ＞5.82 ＞99.9％ |
| Cement sand | Golden yellow | The epidermis Portugal | The pneumonia chain | Suppurative chain | White is read | Read in the torrid zone |
| The thunder Salmonella | Staphylococcus | The grape coccus | Coccus | Coccus | The pearl bacterium | The pearl bacterium | |
| 15 seconds | ＞6.17 ＞99.9％ | ＞6.04 ＞99.9％ | ＞6.45 ＞99.9％ | ＞5.60 ＞99.9％ | ＞5.88 ＞99.9％ | ＞7.18 ＞99.9％ | ＞5.43 ＞99.9％ |
| 30 seconds | ＞6.17 ＞99.9％ | ＞6.04 ＞99.9％ | ＞6.45 ＞99.9％ | ＞5.60 ＞99.9％ | ＞5.88 ＞99.9％ | ＞7.18 ＞99.9％ | ＞5.43 ＞99.9％ |
Experiment showed, that this disinfectant solution has all produced antibacterial effect to each microorganism in each testing time section, each microbial bacterial slip is more than or equal to 99.9%.
Experiment two, biomembrane test
Be in conduit, bionic device, cardiac valve and other non-biological material biomembrane antibacterial on every side and bring very big risk for the patient.Compared with can free bacteria, a biomembrane antibacterial parent can be resisted the natural immunity reaction that stops its growth, also can resist antimicrobial therapy.
There is a contrast experiment to test the curative effect of the local antimicrobials that is used for skin degerming.The bactericidal effect of these skin degerming solvent product for common biomembrane bacterial species mainly tested in this experiment.
Method
The bacterial strain that is used to test comprises methicillin-resistant staphylococcus aureus (MRSA) and methicillin-resistant staphylococcus epidermidis, bacillus pyocyaneus, staphylococcus aureus, staphylococcus epidermidis and vancomycin resistance enterococcus faecalis.The antimicrobial products of test comprises 70% ethanol that contains 2%CHG, contains 72% ethanol of 7.5% povidone iodine, contains 73% propanol of 0.25% Zinc Pyrithione and contains 62% propanol less than 5% povidone iodine.
Experiment has been carried out the free biological sterilization time test to the antibacterial solvent that comprises 1 * 109CFU/ml.Be that every kind of product of 99% adds solvent and tests 15 seconds, 120 seconds afterwards with concentration.After contact, antibacterial solvent and antimicrobial products are changeed as microporous membrane, form the growth of biomembrane parent.Each parent hatching was contacted with antimicrobial products after 48 hours after 15 seconds, 120 seconds.Experiment is calculated the logarithm value of killing of initial bacterial number in free biological sterilization time test process and the biomembrane contact anti-microbial agents process.The results are shown in Table 2, except enterococcus faecalis, other each bacterial biof iotalm all combating microorganisms product has resistant function.
The effect that this disinfectant solution of table 2. is obviously strengthened in reducing bacterial colonization
Free biology and sterilization time test result have shown kill the effect that logarithm value have obvious reinforcement of disinfectant solution at initial bacterial number.
Recommending use in 3 to 4 days in advance to contain the ethanol of CHG, the ethanol that contains Zinc Pyrithione or CHG anticipates possible operative site.Through using repeatedly, CHG and contain Zinc Pyrithione and can both produce antibacterial action, and suppress the skin bacterium cluster.
Experiment three, contrast experiment
Contrast experiment one, disinfectant solution of the present invention and 70% ethanol, the 2%CHG contrast test
One at random, group walk abreast, have the prospective study of open label contrasted the rapid property of this disinfectant solution, 70% ethanol and 2%CHG solvent antibacterial effect and persistency with and safety.The experimental subject age did not suffer from dermatosis, inflammation between 18 to 70 years old, health does not have wound.
Method
Experimental subject is divided into 3 sterilization test groups at random.The test position comprises about abdominal part and zone about groin.Use 3ml single step application device that every kind of sterile products is applied to the test position.The rapid property of each product antibacterial action of check after 10 minutes.Then the wrapping of tulle fenestration is carried out to prevent microbial contamination in the test position.Smear the persistency of a check product antibacterial action after 6 to 24 hours.
Clump count (CFUs) by the test every square centimeter of formation in position is weighed antibacterial effect.
The result
There are 85 in the experimental subject of 106 proof test products and finished this investigation.At abdominal part and pars inguinalis, the not very big difference of the original clump count of experimental subject of three test groups.
Compare with original clump count, the clump count at abdominal part test position all has after 10 minutes, 6 hours, 24 hours and significantly reduces (P=0.0001) smearing three kinds of sterile products.
Three kinds of sterile products in 10 minutes sections and 6 little periods in the not obviously difference of abdominal part test position clump count respectively.But in 24 little periods, the bacterium colony reduction of this disinfectant solution is obviously big than ethanol (P=0.0031) and CHG (P=0.0280).The data result that section drew in 10 minutes meets the abdominal part 2.0log of food and FAD formulation
10Standard.
Conclusion
Three kinds of sterile products are all safe and effective.At abdominal part test position, three kinds of products all meet the standard of skin degerming product before the pass Rhizoma Atractylodis Macrocephalae that food and FAD formulate.In 24 little periods, this disinfectant solution shows than other two kinds of more efficiently antibacterial actions of product.At groin test position,
Contrast experiment two, this disinfectant solution and 70% alcoholic acid contrast experiment
One at random, the unwitting experiment of participant contrasted this disinfectant solution (containing 2%CHG and the 70% alcoholic acid local sterile products that uses) and 70% alcoholic acid antibacterial effect.Experiment test original clump count of 22 experimental subject pars inguinalises.
Method
Experiment to every square centimeter of original clump count greater than 25 and analyze less than 250 experimental subject.In the experimentation, this disinfectant solution and 70% ethanol are applied to the pars inguinalis of experimental subject respectively.The rapid property of both disinfectants of test after one minute, both disinfectant persistency of test after 24 hours.Then wrapping is sealed at the test position.This process repetition every day continues 5 days altogether.
The result
Original clump count that every experimental subject groin scribbles this disinfectant solution and alcoholic acid left part, right part test position is identical.In five days by a definite date experimentation, colony counts after the sterilization that 1 minute section and section test in 24 hours obtain all had significantly than original quantity (P≤0.005) and reduced every day.But the position clump count of smearing this disinfectant solution has significantly persistent, cumulative minimizing (being respectively P≤0.00001 and P≤0.05), and ethanol does not then have this kind effect (being respectively P=0.395 and P≤0.05).To the experiment the 6th day, smear this disinfectant solution after bacterial number reduced 86%.
Conclusion
This disinfectant solution and 70% ethanol have bactericidal effect equally rapidly.But be different from 70% ethanol, the bactericidal effect of this disinfectant solution clearly more has persistency and cumulative bad.
Contrast experiment three, ICU ward conduit care institution are with the contrast test of this disinfectant solution with 10%PI
Use the as easy as rolling off a log infection bloodborne diseases of patient of endovascular treatment device.CHG surmounts PI, becomes catheter insertion site disinfectant choice solvent.An experiment has contrasted the infection effect of used 2% disinfectant solution of ICU patient and 10%PI.
Method
Select the CHG or the PI that are used for skin degerming and catheter insertion site nursing at random for use.Carry out the intravenous injection nursing according to IC standard U regulations.The replacing of conduit and the acquisition of culture fluid all should be operated by ICU staff.The patient was inserted site infection in per 48 hours, the relevant bacteremia of catheter infections and conduit detects.
The result
Experiment comprises 164 patients altogether, and wherein CHG group and PI group are each 82.Patient characteristic is similar.Two groups of patients' catheter insertion site infection rate does not have significant difference.The CHG group is respectively 4.9% and 18.3% with the relevant infectious disease hair of the conduit infection rate of PI group.Former bloodborne diseases hair infection rate of CHG group and PI group is respectively 1.2% and 9.8%.Per 1000 conduits use Japan-China, and the catheter infections of CHG group and PI group is respectively 5.1 and 14.5, and former blood infection is respectively 1.3 and 7.7.In the CHG group, the disinfection cost that is used for every patient has reduced by 850 to 1202 dollars.Experimental result sees Table 3.
The infection rate of table 3.CHG and PI
| Infection rate CHG PI |
| Conduit infections relating disease hair infection rate 4.9% 18.3% |
| Constitutional BSI hair infection rate 1.2% 9.8% |
| Per 1000 conduits use day |
| Catheter infections rate 5.1 14.5 |
| Constitutional BSI 1.3 7.7 |
Conclusion
Under the ICU ward environment, 2%CHG is having better effect than PI aspect reduction conduit infections relating rate and former blood infection rate.And infection rate reduction also minimizing disinfection cost.
Compositions of the present invention or its pharmaceutically acceptable salt have following characteristics: Gram-positive and gram negative bacteria are had bactericidal effect rapidly; The antibiosis effect is lasting, prevents that the skin bacterium recovery time from can reach 48 hours at least; At blood, still can keep good result in the biomaterial of serum and rich in proteins; Zest is little, and is easy to use; The present invention can very clearly distinguish and do the disinfectant zone by adding coloring agent, prevents that medical care person is not used as the position that wiping was handled in the disinfectant position, increases the safety of sterilizing operation.
The specific embodiment:
Further specify the present invention by following examples, but not as restriction of the present invention.
Embodiment 1,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
Sunset yellow 0.8kg
Pure water surplus (about 20kg).
Preparation method:
1, is the dissolving of 20% chlorhexidine gluconate with pure water with 10kg concentration earlier, mixes and stirred 5 minutes;
2, adding 70L concentration again is 99.9% ethanol, mixes to stir to add the sunset yellow of 0.8kg and an amount of wetting agent after 5 minutes, and stabilizing agent, and pure water evenly stirred 10 minutes;
3, censorship, fill, encapsulation.
Embodiment 2,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 2.5kg
99.9% ethanol 50L
Sunset yellow 0.5kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 3,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 25kg
99.9% ethanol 90L
Sunset yellow 1.5kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 4,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 25kg
99.9% ethanol 90L
Gentian Violet 1.5kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 5,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
Gentian Violet 0.8kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 6,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
The red 1kg of relation by marriage fat
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 7,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
The red 0.9kg of relation by marriage fat
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 8,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
Lemon yellow 0.8kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 9,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
Bright blue 0.8kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 10,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine acetate solution 10kg
99.9% ethanol 70L
Sunset yellow 0.8kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 11,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine acetate solution 10kg
99.9% ethanol 70L
Lemon yellow 0.8kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 12,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine acetate solution 10kg
99.9% ethanol 70L
Gentian Violet 0.8kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Embodiment 13,
The prescription that compositions of the present invention or its pharmaceutically acceptable salt are calculated by weight is: (is standard with the 100L product)
20% chlorhexidine gluconate solution 10kg
99.9% isopropyl alcohol 70L
Sunset yellow 0.8kg
Pure water surplus (about 20kg).
Preparation method is with embodiment 1.
Claims (10)
1, the pharmaceutical composition that contains hibitane or its pharmaceutically acceptable salt and at least a coloring agent.
2, the compositions of claim 1 is characterized in that, also contains the medicine acceptable carrier.
3, the compositions of claim 1, it is characterized in that, the salt of described hibitane is hibitane and mineral acid or the formed salt of organic acid, is selected from hydrochlorate, hydrobromate, phosphate, sulfate, acetate, trifluoroacetate, citrate, maleate, oxalates, succinate, benzoate, tartrate, fumarate, mandelate, Ascorbate, malate, mesylate, tosilate, gluconate or acetate.
4, the compositions of claim 4 is characterized in that, described salt is selected from gluconate and acetate.
5, the compositions of claim 5 is characterized in that, described compositions is selected from an innings ointment, solution, suppository, lotion, cream, obedient agent, varnish, mixture.
6, the compositions of claim 1 is characterized in that, described coloring agent is that medical science and pharmacology go up acceptable any pigment.
7, the compositions of claim 1 is characterized in that, described coloring agent is selected from sunset yellow, lemon yellow, Gentian Violet, red, the bright orchid of relation by marriage fat.
8, the compositions of claim 1 is characterized in that, its composition comprises: the salt of hibitane, at least a coloring agent, ethanol or isopropyl alcohol, water.
9, the compositions of claim 1 is characterized in that, described composite formula is composed as follows
The salt 0.5-5% of hibitane
Ethanol 50-90%
Coloring agent 0.5-1.5%
All the other are water.
10, claim 1 compositions, it is characterized in that it is composed as follows to fill a prescription:
20% chlorhexidine gluconate solution 10kg
99.9% ethanol 70L
Sunset yellow 0.8kg
Water surplus
Make 100L
Its preparation method is as follows:
Be the dissolving of 20% chlorhexidine gluconate with pure water with 10kg concentration earlier, mix and stirred 5 minutes;
Add 70L concentration again and be 99.9% ethanol, mix to stir and add the sunset yellow of 0.8kg and an amount of wetting agent after 5 minutes, stabilizing agent, and pure water evenly stirred 10 minutes;
Censorship, fill, encapsulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101475214A CN101336910A (en) | 2008-08-20 | 2008-08-20 | Chlorhexidine composition with colouring function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101475214A CN101336910A (en) | 2008-08-20 | 2008-08-20 | Chlorhexidine composition with colouring function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101336910A true CN101336910A (en) | 2009-01-07 |
Family
ID=40211176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101475214A Pending CN101336910A (en) | 2008-08-20 | 2008-08-20 | Chlorhexidine composition with colouring function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101336910A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2499913A1 (en) * | 2011-03-14 | 2012-09-19 | Combino Pharm, S.L. | Antiseptic solutions comprising chlorhexidine or its salt and an anionic dye and their preparation |
| EP2499914A1 (en) * | 2011-03-14 | 2012-09-19 | Combino Pharm, S.L. | Antiseptic solutions comprising chlorhexidine or its salt and an anionic dye and their preparation |
| US20120238635A1 (en) * | 2011-03-14 | 2012-09-20 | Combino Pharm, S.L. | Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound and Process Therefor |
| CN104473972A (en) * | 2014-11-28 | 2015-04-01 | 成都顺发消洗科技有限公司 | Method for preparing skin disinfectant |
| CN104490936A (en) * | 2014-11-28 | 2015-04-08 | 成都顺发消洗科技有限公司 | Skin disinfectant |
| CN105388243A (en) * | 2015-12-09 | 2016-03-09 | 中国检验检疫科学研究院 | Method for measuring hexamidine, chlorhexidine, and salts thereof in cosmetics |
| CN107595827A (en) * | 2017-09-29 | 2018-01-19 | 山东新华医疗器械股份有限公司 | 2% chlorhexidine gluconate alcohol thimerosal and preparation method thereof |
-
2008
- 2008-08-20 CN CNA2008101475214A patent/CN101336910A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2499913A1 (en) * | 2011-03-14 | 2012-09-19 | Combino Pharm, S.L. | Antiseptic solutions comprising chlorhexidine or its salt and an anionic dye and their preparation |
| EP2499914A1 (en) * | 2011-03-14 | 2012-09-19 | Combino Pharm, S.L. | Antiseptic solutions comprising chlorhexidine or its salt and an anionic dye and their preparation |
| US20120238635A1 (en) * | 2011-03-14 | 2012-09-20 | Combino Pharm, S.L. | Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound and Process Therefor |
| ES2397638R1 (en) * | 2011-03-14 | 2013-04-29 | Combino Pharm Sl | ANTISEPTIC SOLUTIONS OF A DERIVATIVE OF DI (4-CHLORINE-PHENYLDIGUANIDE) AND ITS PROCEDURES |
| US9149042B2 (en) * | 2011-03-14 | 2015-10-06 | Medichem, S.A. | Antiseptic solution of di(4-chloro-phenyldiguanido) compound and process therefor |
| EP2499914B1 (en) | 2011-03-14 | 2017-12-20 | Medichem, S.A. | Antiseptic solutions comprising di-(4-chlorophenyldiguanidino)-hexane and an anionic dye and their preparation |
| CN104473972A (en) * | 2014-11-28 | 2015-04-01 | 成都顺发消洗科技有限公司 | Method for preparing skin disinfectant |
| CN104490936A (en) * | 2014-11-28 | 2015-04-08 | 成都顺发消洗科技有限公司 | Skin disinfectant |
| CN105388243A (en) * | 2015-12-09 | 2016-03-09 | 中国检验检疫科学研究院 | Method for measuring hexamidine, chlorhexidine, and salts thereof in cosmetics |
| CN107595827A (en) * | 2017-09-29 | 2018-01-19 | 山东新华医疗器械股份有限公司 | 2% chlorhexidine gluconate alcohol thimerosal and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11103471B2 (en) | Antimicrobials and methods of use thereof | |
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| CN101336910A (en) | Chlorhexidine composition with colouring function | |
| Moslemi et al. | Antimicrobial activity of Artemisia absinthium against surgical wounds infected by Staphylococcus aureus in a rat model | |
| CN106793784A (en) | Vegetalitas antimicrobial compositions | |
| CN107812137A (en) | A kind of draft skin bacteriostatic gel of propolis-containing and preparation method thereof | |
| CN105078793A (en) | Antibacterial gel hand cleanser and preparation method thereof | |
| CN106818837B (en) | Biological antibiotic polypeptide formulations, preparation method and applications | |
| CN107961399A (en) | A kind of water-based body lotion containing complex antimicrobials | |
| CN103813799A (en) | Disinfecting formulations and uses thereof | |
| CA2733780C (en) | Gentle, non-irritating, non-alcoholic skin disinfectant | |
| US8173147B2 (en) | Gentle, non-irritating, non-alcoholic skin disinfectant | |
| CN112999331A (en) | Preparation method and application of biological sterilization preparation | |
| CN111588723B (en) | Gynecological disinfectant and preparation method thereof | |
| CN105997964A (en) | Efficacy type sterilization and disinfection liquid containing natural citral-bletilla striata polysaccharide polymer and preparation method thereof | |
| CN106267329A (en) | A kind of plants essential oil gel dressing and its preparation method and application | |
| CN104523748A (en) | Compound iodine disinfectant and preparation method and application thereof | |
| Kub et al. | Comparison of well diffusion, disc diffusion and broth dilution methods for antimicrobial activity of Andrographis paniculata herbal gel against acne-associated pathogen. | |
| CN1823753A (en) | Cream for treating beriberi and its production method | |
| CN111991317B (en) | Wash-free hand gel containing Chinese herbal medicine components and preparation method thereof | |
| RU2725991C1 (en) | Liquid disinfectant and antiseptic composition for use in medicine and veterinary science | |
| CN108938559B (en) | DNA gel sterilization material, preparation method thereof and application of DNA gel sterilization material as sterilization material | |
| Steczko et al. | In vitro and in vivo evaluation of efficacy of citrate/methylene blue/parabens/IPA solution as a skin disinfectant | |
| EP3106172A1 (en) | Antimicrobial agents and their use | |
| WO2024144724A1 (en) | A topical preparate based on origanum majorana l. essential oil with proliferative and antimicrobial effects in wound treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090107 |